Novo Nordisk stock falls sharply as Capital Markets Day disappoints investors

Novo Nordisk stock (ISIN DK0060534915) came under heavy pressure after the company’s Capital Markets Day, with the shares falling about 7.7 percent in Copenhagen on September 21, 2026 as investors were unconvinced by the new long-term targets.

Capital Markets Day triggers sharp share-price reaction

According to AD HOC NEWS, Novo Nordisk A/S closed at DKK 307.30 on Nasdaq Copenhagen on September 21, 2026, representing a 7.7 percent decline on the day after the Capital Markets Day targets failed to reassure investors.

On the same date, the US-listed American Depositary Receipt (ADR) NVO finished New York trading at USD 39.80, down 7.96 percent, illustrating that the negative reaction to the company’s strategic ambitions was global and not limited to the home market, as reported by FinanceFeeds.

Long-term targets seen as insufficiently convincing

Novo Nordisk used its Capital Markets Day in London on September 21, 2026 to outline a long-term strategic plan and financial ambitions through 2030 and beyond, including the goal of introducing at least five new blockbuster drugs by 2030 and targeting pipeline sales of more than DKK 150 billion by 2035, according to Traders Union.

As Morningstar Europe reports, Novo’s management presented 2030 financial targets featuring mid-single-digit top-line growth and roughly steady operating margins, prompting Morningstar to slightly lower its fair value estimate for Novo Nordisk from DKK 285 to DKK 275 while maintaining a wide economic moat assessment.

Analyst price targets cut after the sell-off

The Capital Markets Day and subsequent share-price decline have led to a wave of updated analyst views. Jefferies analyst Michael Leuchten maintained a Hold rating and set a price target of DKK 275, according to TipRanks, while the same level is echoed in a French-language analyst overview where Jefferies reduced its target from DKK 285 to DKK 275 but kept a Conserver (Hold) stance, as shown by Zonebourse.

According to the same Zonebourse overview, UBS analyst Matthew Weston confirmed a Neutral view with a price target of DKK 332, while Deutsche Bank reduced its target from DKK 265 to DKK 245 and kept a Sell recommendation, and DNB Carnegie lowered its target from DKK 420 to DKK 400 while still advising Buy.

Valuation, patent risk and growth transition in focus

For investors, the key debate now centers on whether the revised long-term ambitions justify Novo Nordisk’s valuation after the sell-off and how the company will navigate the transition away from current flagship obesity and diabetes drugs as patent expirations approach. As FinanceFeeds highlights, investors questioned Novo’s ability to offset revenue losses expected as exclusivity for semaglutide-based therapies such as Wegovy and Ozempic begins to expire in the early 2030s.

Morningstar’s slight reduction of its fair value estimate to DKK 275 reflects a more cautious stance on research and development spending, but it also assigns more longevity to the oral Wegovy formulation patents into the late 2030s, providing a potential buffer to the patent cliff scenario around 2032, according to Morningstar Europe.

Stock remains volatile after the gap down

In New York, Novo Nordisk’s ADR NVO showed pronounced volatility, with shares gapping down from a prior close of USD 43.24 to an opening level of USD 41.05 and last trading around USD 39.82 in heavy volume of 9,863,855 shares on September 21, 2026, according to MarketBeat.

As of September 21, 2026 this closing ADR price of USD 39.80 on the New York Stock Exchange, combined with a reported market capitalization of about USD 176.1 billion referenced by Sina Finance, places the stock roughly one fifth below levels seen at its 2024 peak, underscoring how the Capital Markets Day has accelerated an already ongoing derating.

Fact box

More news and analyses on Novo Nordisk stock